| **DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION** | **DRUG TYPE AND USE** | **LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION** | **PBAC OUTCOME** |
| --- | --- | --- | --- |
| EPINEPHRINE  I.M Injection, 150 micrograms in 0.3 mL, pen device  I.M Injection, 300 micrograms in 0.3 mL, pen device  Symjepi®  Emerge Health Pty Ltd  New listing  (Minor Submission) | Acute allergic reactions including anaphylaxis | To request the Authority Required PBS listing of Symjepi® for the emergency treatment of allergic reactions. | The PBAC recommendation cannot be made public until the TGA outcome is known. |
| NIVOLUMAB + IPILIMUMAB  Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL Injection concentrate for I.V. infusion 100 mg in 10 mL  Opdivo®  Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL  Yervoy®  Bristol-Myers Squibb Australia Pty Ltd  New listing (Major Submission) | Non-small cell lung cancer (NSCLC) | To request an extension to the current Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listings for nivolumab and ipilimumab to include the first-line treatment of patients with Stage IV NSCLC. | The PBAC recommendation cannot be made public until the TGA outcome is known. |